Huiyuan Hou1, Sasan Moghimi1, James A Proudfoot1, Elham Ghahari1, Rafaella C Penteado2, Christopher Bowd1, Diya Yang1, Robert N Weinreb3. 1. Hamilton Glaucoma Center and Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California. 2. Hamilton Glaucoma Center and Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California; Department of Ophthalmology, University of São Paulo, São Paulo, Brazil. 3. Hamilton Glaucoma Center and Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California. Electronic address: rweinreb@ucsd.edu.
Abstract
PURPOSE: To characterize the change rate of ganglion cell complex (GCC) thickness and macular vessel density in healthy, preperimetric glaucoma and primary open-angle glaucoma (POAG) eyes. DESIGN: Prospective, longitudinal study. PARTICIPANTS: One hundred thirty-nine eyes (23 healthy eyes, 36 preperimetric glaucoma eyes, and 80 POAG eyes) of 94 patients who had at least 3 visits were included from the Diagnostic Innovations in Glaucoma Study. The mean follow-up was 2.0 years for healthy eyes, 2.6 years for preperimetric glaucoma eyes, and 2.6 years for POAG eyes. METHODS: OCT angiography (OCTA)-based vessel density and OCT-based structural thickness of the same 3×3-mm2 GCC scan slab were evaluated. The dynamic range-based normalized rates of vessel density and thickness change were calculated and compared within each diagnostic group. The association between the rates of thickness and vessel density change and potential factors were evaluated. MAIN OUTCOME MEASURES: The rates of GCC thinning and macular vessel density loss. RESULTS: Significant rates of GCC thinning and macular vessel density decrease were detectable in all diagnostic groups (all P < 0.05). In healthy eyes and preperimetric glaucoma eyes, the normalized rates of GCC thinning and macular vessel density decrease were comparable (all P > 0.1). In contrast, the normalized rate (mean, 95% confidence interval) of macular vessel density decrease in the POAG eyes (-7.12 [-8.36, -5.88]%/year) was significantly faster than GCC thinning (-2.13 [-3.35, -0.90]%/year; P < 0.001). In the POAG group, more than two thirds of the eyes showed faster macular vessel density decrease than GCC thinning; faster macular vessel density decrease rate was associated significantly with worse glaucoma severity (P = 0.037). The association between GCC thinning rate and glaucoma severity was not significant (P = 0.586). Intraocular pressure during follow-up significantly affected the rate of GCC thinning in all groups (all P < 0.05) but showed no association with the rate of macular vessel density decrease. CONCLUSIONS: Both GCC thinning and macular vessel density decrease were detectable over time in all diagnostic groups. In POAG eyes, macular vessel density decrease was faster than GCC thinning and was associated with severity of disease. Macular vessel density is useful for evaluating glaucoma progression, particularly in more advanced disease.
PURPOSE: To characterize the change rate of ganglion cell complex (GCC) thickness and macular vessel density in healthy, preperimetric glaucoma and primary open-angle glaucoma (POAG) eyes. DESIGN: Prospective, longitudinal study. PARTICIPANTS: One hundred thirty-nine eyes (23 healthy eyes, 36 preperimetric glaucoma eyes, and 80 POAG eyes) of 94 patients who had at least 3 visits were included from the Diagnostic Innovations in Glaucoma Study. The mean follow-up was 2.0 years for healthy eyes, 2.6 years for preperimetric glaucoma eyes, and 2.6 years for POAG eyes. METHODS: OCT angiography (OCTA)-based vessel density and OCT-based structural thickness of the same 3×3-mm2 GCC scan slab were evaluated. The dynamic range-based normalized rates of vessel density and thickness change were calculated and compared within each diagnostic group. The association between the rates of thickness and vessel density change and potential factors were evaluated. MAIN OUTCOME MEASURES: The rates of GCC thinning and macular vessel density loss. RESULTS: Significant rates of GCC thinning and macular vessel density decrease were detectable in all diagnostic groups (all P < 0.05). In healthy eyes and preperimetric glaucoma eyes, the normalized rates of GCC thinning and macular vessel density decrease were comparable (all P > 0.1). In contrast, the normalized rate (mean, 95% confidence interval) of macular vessel density decrease in the POAG eyes (-7.12 [-8.36, -5.88]%/year) was significantly faster than GCC thinning (-2.13 [-3.35, -0.90]%/year; P < 0.001). In the POAG group, more than two thirds of the eyes showed faster macular vessel density decrease than GCC thinning; faster macular vessel density decrease rate was associated significantly with worse glaucoma severity (P = 0.037). The association between GCC thinning rate and glaucoma severity was not significant (P = 0.586). Intraocular pressure during follow-up significantly affected the rate of GCC thinning in all groups (all P < 0.05) but showed no association with the rate of macular vessel density decrease. CONCLUSIONS: Both GCC thinning and macular vessel density decrease were detectable over time in all diagnostic groups. In POAG eyes, macular vessel density decrease was faster than GCC thinning and was associated with severity of disease. Macular vessel density is useful for evaluating glaucoma progression, particularly in more advanced disease.
Authors: Takuhei Shoji; Linda M Zangwill; Tadamichi Akagi; Luke J Saunders; Adeleh Yarmohammadi; Patricia Isabel C Manalastas; Rafaella C Penteado; Robert N Weinreb Journal: Am J Ophthalmol Date: 2017-07-20 Impact factor: 5.258
Authors: Huiyuan Hou; Sasan Moghimi; Linda M Zangwill; Takuhei Shoji; Elham Ghahari; Rafaella C Penteado; Tadamichi Akagi; Patricia Isabel C Manalastas; Robert N Weinreb Journal: Am J Ophthalmol Date: 2018-11-26 Impact factor: 5.258
Authors: Min Hee Suh; Linda M Zangwill; Patricia Isabel C Manalastas; Akram Belghith; Adeleh Yarmohammadi; Felipe A Medeiros; Alberto Diniz-Filho; Luke J Saunders; Siamak Yousefi; Robert N Weinreb Journal: Ophthalmology Date: 2016-08-31 Impact factor: 12.079
Authors: Harsha L Rao; Zia S Pradhan; Robert N Weinreb; Hemanth B Reddy; Mohammed Riyazuddin; Srilakshmi Dasari; Meena Palakurthy; Narendra K Puttaiah; Dhanaraj A S Rao; Carroll A B Webers Journal: Am J Ophthalmol Date: 2016-08-30 Impact factor: 5.258
Authors: Yali Jia; Eric Wei; Xiaogang Wang; Xinbo Zhang; John C Morrison; Mansi Parikh; Lori H Lombardi; Devin M Gattey; Rebecca L Armour; Beth Edmunds; Martin F Kraus; James G Fujimoto; David Huang Journal: Ophthalmology Date: 2014-03-12 Impact factor: 12.079
Authors: Hana L Takusagawa; Liang Liu; Kelly N Ma; Yali Jia; Simon S Gao; Miao Zhang; Beth Edmunds; Mansi Parikh; Shandiz Tehrani; John C Morrison; David Huang Journal: Ophthalmology Date: 2017-07-01 Impact factor: 12.079
Authors: Gilbert T Feke; Peter J Bex; Christopher P Taylor; Douglas J Rhee; Angela V Turalba; Teresa C Chen; Martin Wand; Louis R Pasquale Journal: Am J Ophthalmol Date: 2014-04-05 Impact factor: 5.258
Authors: Alireza Kamalipour; Sasan Moghimi; Huiyuan Hou; James A Proudfoot; Takashi Nishida; Linda M Zangwill; Robert N Weinreb Journal: Am J Ophthalmol Date: 2021-11-19 Impact factor: 5.488
Authors: Nevin W El-Nimri; Sasan Moghimi; Rafaella C Penteado; Elham Ghahari; Diya Yang; Nicole Brye; James Proudfoot; Jiun L Do; Andrew Camp; Matthew Salcedo; Veronica Rubio; Robert N Weinreb Journal: Am J Ophthalmol Date: 2022-05-06 Impact factor: 5.488
Authors: Nevin W El-Nimri; Patricia Isabel C Manalastas; Linda M Zangwill; James A Proudfoot; Christopher Bowd; Huiyuan Hou; Sasan Moghimi; Rafaella C Penteado; Jasmin Rezapour; Eren Ekici; Takuhei Shoji; Elham Ghahari; Adeleh Yarmohammadi; Robert N Weinreb Journal: J Glaucoma Date: 2021-06-01 Impact factor: 2.290
Authors: Xiongfei Liu; Alicia Lau; Huiyuan Hou; Sasan Moghimi; James A Proudfoot; Eric Chan; Jiun Do; Andrew Camp; Derek Welsbie; Carlos Gustavo de Moraes; Christopher A Girkin; Jeffrey M Liebmann; Robert N Weinreb Journal: Ophthalmol Glaucoma Date: 2021-01-30